The KATO-III cell-derived stomach cancer amplified (K-sam) gene was identified initially as a gene amplified and overexpressed in poorly differentiated human stomach cancers. It is now known as fibroblast growth factor receptor 2 (FGFR2). It is also known as bacteria-expressed kinase (BEK), keratinocyte growth factor receptor (KGFR), Jackson-Weiss syndrome (JWS), craniofacial dysostosis 1 (CFD1), BBDS, CEK3, ECT1, TK14, TK25, BFR-1, and CD332. The FGFR2 gene encodes two alternatively spliced isoforms, FGFR2b (expressed in epithelial cells) and FGFR2c (expressed in mesenchymal cells). The extracellular portions of FGFR2b and FGFR2c interact with fibroblast growth factors, activating a cascade of downstream signals that regulate mitogenesis and differentiation. FGFR2 plays an essential role in osteoblast differentiation, proliferation, and apoptosis, and is required for normal skeletal development. Gene amplification or missense mutations of the FGFR2 gene result in aberrant signaling, and are associated with a variety of cancers, including gastric, lung, breast, ovarian, and endometrial cancers. FGFR2 mutations are also associated with Crouzon syndrome, Pfeiffer syndrome, craniofacial dysostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, and Saethre-Chotzen syndrome.
This product is an affinity-purified IgG antibody that recognizes human FGFR2/K-sam. The antibody was raised in rabbit using a synthetic peptide. It can be used for Western blot (WB) detection or immunohistochemical (IHC) detection of human FGFR2/K-sam protein.